Inhibition of γ-Secretase Activity by Helical β-Peptide Foldamers
Citations Over TimeTop 10% of 2009 papers
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder pathologically characterized by extensive extracellular deposition of amyloid-beta (Abeta) peptides as senile plaques, and inhibition of "amyloidogenic" amyloid precursor protein (APP) processing by gamma-secretase is an important strategy for prevention and treatment of AD. Here we show that beta-peptide foldamers designed to adopt a 12-helical conformation in solution are potent and specific inhibitors of gamma-secretase. Subtle modifications that disrupt helicity substantially reduce inhibitory potency, suggesting that helical conformation is critical for effective inhibition. These beta-peptides competed with helical peptide-type inhibitor, suggesting that they interact with the substrate binding site of gamma-secretase. The beta-peptide with inhibitory activity at nanomolar concentration should be a useful lead compound for development of gamma-secretase-specific inhibitors and molecular tools to explore substrate recognition by intramembrane proteases.
Related Papers
- → Inhibition and Modulation of γ-Secretase for Alzheimer's Disease(2008)140 cited
- → Retention in Endoplasmic Reticulum 1 (RER1) Modulates Amyloid-β (Aβ) Production by Altering Trafficking of γ-Secretase and Amyloid Precursor Protein (APP)(2012)34 cited
- → Amyloid metabolism and secretases in Alzheimer’s disease(2001)27 cited
- → Is γ-secretase a multienzyme complex for membrane protein degradation?(2002)11 cited
- → Faculty Opinions recommendation of Gamma-secretase activating protein is a therapeutic target for Alzheimer's disease.(2010)